newsfilter
← Latest News
Business Wire·

AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies

Breakthrough in AI-powered drug discovery validates HYFT™-driven peptide design, with broad potential across multiple therapeutic areas ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA), a leader in AI-powered drug